A Value-Based Framework in the Clinical Integration of PARP Inhibitors in the Management of Ovarian Cancer

This activity is jointly provided by AMCP and Medscape Oncology.



AMCP and Medscape Oncology recently launched “A Value-Based Framework in the Clinical Integration of PARP Inhibitors in the Management of Ovarian Cancer,” featuring Dr. Kathleen Moore and Dr. Bradley Monk. This activity focuses on the clinical utility of PARP inhibitors in ovarian cancer, considerations for balancing efficacy and safety in clinical practice, and the important role of the managed care pharmacists and clinical pharmacists in optimizing the patient's outcome

 

This activity is designed for managed care pharmacists, clinical pharmacists, and oncologists.

 

Participants who complete this activity will:

 

  •         Have increased knowledge regarding the
  •         Clinical role of PARP inhibitors in the management of advanced OC
  •         Cost-effectiveness analyses and pharmacoeconomic data on PARP inhibitor therapy for OC
  •         Demonstrate greater confidence in their ability to utilize roles of the healthcare team for optimizing PARP inhibitor therapy in the management of patients with advanced OC

 

Value-Based Framework in the Clinical Integration of PARP Inhibitors in the Management of Ovarian Cancer

Authors: Kathleen N. Moore, MD; Bradley Monk, MD, FACOG, FACS; Stephanie L. Ho, PharmD, BCPSF

CME / ABIM MOC / CE Released: 10/4/2021

Valid for credit through: 10/4/2022

 

If you are already registered with Medscape follow this link below to:  

Value-Based Framework in the Clinical Integration of PARP Inhibitors in the Management of Ovarian Cancer